Proscia Upgrades Concentriq Platform with AI-Driven Pathology Tools — Proscia Inc.

Event summary

Proscia launched the fifth generation of its Concentriq platform on June 17, 2026, integrating advanced AI capabilities for pathologists and scientists.
The new architecture unifies images, metadata, and contextual data to support drug discovery, development, and case review.
Concentriq is used by diagnostic laboratories managing 12 million patient cases annually and 16 of the top 20 pharmaceutical companies.
The platform aims to reduce manual effort and accelerate case review, biomarker discovery, and clinical trial success.

The big picture

Proscia's upgrade to its Concentriq platform comes at a time when pathologists are overwhelmed by workloads and scientists face pressure to accelerate drug discovery. The integration of AI into pathology tools is a strategic move to enhance efficiency and precision in medical diagnostics. With 16 of the top 20 pharmaceutical companies already using Concentriq, Proscia is well-positioned to capitalize on the growing demand for advanced digital pathology solutions.

What we're watching

Adoption Pace: How quickly diagnostic laboratories and biopharmaceutical companies will adopt the fifth generation of Concentriq, given its advanced AI capabilities.
Regulatory Compliance: Whether Proscia can maintain compliance with evolving regulatory standards, particularly in the EU and Canada, while expanding its platform's capabilities.
Competitive Positioning: The pace at which Proscia can differentiate itself from competitors in the digital pathology space, leveraging its AI-driven advancements.